

מראה מקום- 303 המטולוגיה

מס' שאלה	מראה מקום
1	Hoffman Hematology 8 th Ed p1801
2	Williams Hematology 10 th Ed
3	Blood 2025 145 (20) 2275-82
4	Williams Hematology 10th edition, Chapter 138 - Blood Procurement and Red Cell Transfusion
	Williams Hematology 10th edition, Chapter 56 - Alloimmune Hemolytic Disease of the Fetus and Newborn
	Berentsen S. NEJM 2021 – Autoimmune Hemolytic Anemia
5	Williams Hematology 10th edition, Chapter 55 - Hemolytic Anemia Resulting from Immune Injury
6	Bouzat P et al. JAMA 2023 – PROCOAG trial
7	Hoffman-8th-ed-Ch.-112-Principles-of-RBC-transfusion
8	55 Williams Hematology 10 th edition, chapter
9	
10	Onco-Cardiology: Focus on Cardiac Complications of Hematologic Treatments הופמן
11	, Rodriguez-Otero, Paula et al. The Lancet Oncology, Volume 25, Issue 5, e205 - e216 . 2024
12	Hoffman Chapter 58, 900-936
13	Hoffman chapter 99
14	Hoffman chapter 99
15	ASH EDU 2024 Should we use bisphosphonates to treat bone complications in sickle cell disease
16	מחקר
17	
18	Chapter 30, 350-395 הופמן
19	Einsele et al., Blood 2020, 10.1182/blood.2019000956. Hoffman, page 1576, 1774
20	Chapter 26, 295-302 פרק 26 הופמן
21	:N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. PMID 39292927
22	
23	Chapter 110, 1770-1784 הופמן
	Lancet 2024; 404: 1940–54
	Lancet Haematology, Volume 7, Issue 7, e511 - e522
24	Lancet Oncol 2020; 21: 978–88
25	.Barraclough A, Hawkes EA. ASH Education Book 2024; pp. 318–320 מקור:
26	.Wright GW et al., Blood 2020;135:1759–1771 מקור:
27	Volume 146, Issue 15, 9 October 2025, Pages 1812-1823
28	Wang M et al., J Clin Oncol. 2025;43:145–158 Dreyling M et al., Blood. 2022;140:151–163
29	Roskowseski M et al., Blood 2023;142:1426-1436
30	Rubinstein JL, JCO 2022
31	.Falini B, Tiacci E. Hairy-Cell Leukemia. N Engl J Med. 2024;391:1328–1341.Tiacci E et al Blood. 2022;140(18):1963–1976
32	Mazyar Shadman, Matthew S. Davids. How I treat patients with CLL after prior treatment . with a covalent BTK inhibitor and a BCL-2 inhibitor. Blood. 2025
33	Hallek et al. Blood 2018 131(25):2745-2760
34	.Byrd JC et al. N Engl J Med. 2013;369:32–42. PMID: 23782158. Herman SEM et al Leukemia. 2014;28:2109–2113. PMID: 24699307
35	.Parikh SA et al. Blood. 2021;138(2):149–159 Abdelbaky SB et al. Blood 1757–1752:(17)143;2024
36	.Ruan J. et al. Blood. 2023;141(18):2165–2177 .Alaggio R. et al. Leukemia (WHO-HAEM5, Revised 2022) .1748–36:1720;2022
37	Treatment of RR follicular lymphoma, which treatment for which patient for which line of therapy, BLOOD2025
38	.Zhou Y, Zucca E, et al. <i>Management of marginal zone lymphomas Hematology Am Soc Hematol Educ .Program</i> 687–676:(1);2022
39	Hoffman 8 th edition
40	CVID ASH EDU 2024
41	ASH EDU 2024 Luspatercept: a treatment for ineffective erythropoiesis in thalassemia
42	ASH EDU 2024 Diagnosis and management of hereditary hemochromatosis
43	HOFFMAN MEGALOBlastic ANEMIA Drug-Induced Defects
44	HOFFMAN IRON DEFICIENCY How to Manage Hypersensitivity Reactions to Intravenous Iron
45	HOFFMAN Anemia of Chronic Inflammation
46	Chapter 54, 769-781 Hoffman 8 th edition
47	Hematology: Basic Principles and Practice (Hoffman) Chapter: structure, biology and function of Von-Willebrand factor
48	Mañé I, et al New England Journal of Medicine. 2025 Apr 10;392(14):1363-73.

Andrew D. Mumford, First published: 06 August 2014. https://doi.org/10.1111/bjh.13058	49
Chowdary P, et al . Haemophilia. Lancet. 2025 Mar 1;405(10480):736-750.	50
Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline. Raza Alikhan, et al BJH, 2024	51
. Apixaban for Extended Treatment of Provoked Venous Thromboembolism https://orcid.org/0000-0003-1407-5276 , Behnood Bikdeli, M.D., Arvind K. Pandey, HI-PRO Trial Investigators* , NEJM 2025	52
.Blood 2024; 143 (23): 2425–2432 מקור:	53
) "Williams Hematology, 10th ed, chapter 32, page 2375 .(-Br J Haematol 205.3 (2024): 855 .880 (	54
.Reference: Chan N et al. Direct oral anticoagulants: evidence and unresolved issues .Lancet 2020; 396: 1767-1776	55
הופמן 2335 מהדורה 8 עמוד	56
.Reference: Busse. Et al.. British Journal of Haematology 2024; 204: 1176-1177	57
Williams Hematology 10 th edition, chapter 117	58
הופמן 2150 עמוד	59
NEJM 2019;380:1825-1833	60
N Engl J Med 2019;380:1825-1833	61
	62
Blood2025 Jun 12;145(24):2914-2926	63
Hematology Am Soc Hematol Educ Program (2024) 2024 (1): 259–269	64
:Elisabetta Abruzzese et al. Blood. 2025 Aug 4;blood.2024026513. doi blood.Abruzzese E, et al. Blood. 2024;144:2435–6/10.1182	65
Berman E. How I treat. Blood. 2022 May 26;139(21):3138-3147.	66
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):122-128.	67
ASH Education Book 2023 p662	68
Br J Haematol.2024 Feb;204(2):402-414	69
Hematology: Basic Principles and Practice (Hoffman 8th edition 2022) Br J Haematol. 2025 .Jan;206(1):44-60	70
J Clin Oncol 35:3844-3850	71
MF ASH EDUCATION 2023 פרק על רפרנס	72
Reference ASH EDUCATIONAL 2024	73
Lancet 2024 Jul 27;404(10450):341-352.	74
ASH educational 2024	75
ASH educational BOOK; Dec. 2023 pages 501-509	76
Blood .(Supplement 1): 5963 144 (2024)	77
Hematology basic principles and practice 8th edition – Chapter 62, (Page1004)	78
.N Engl J Med. 2020 Dec 31;383(27):2628-2638	79
Lancet. 2023 Jul 29;402(10399):373-385. Lancet Haematol. 2024 Sep;11(9):e646-e658. N Engl J Med. 2020 Jan 9;382(2):140-151. Lancet. 2024 Jan 20;403(10423):249-260.	80
Garcia ae al, Blood 2025 https://doi.org/10.1182/blood.2024025464 Blood (2025) 145 (18): 2002–2011. https://doi.org/10.1182/blood.2024025271	81
doi: 10.1200/JCO.24.00826 . Epub 2024 Aug 9	82
J Clin Oncol 38, 623-632(2020). DOI:10.1200/JCO.19.01406	83
Eighth Edition Hoffman, Ronald, MD Chapter 60, pages: 973	84
: Pemmaraju N et al Blood 2023	85
Lancet. 2023 Oct 14;402(10410):1328. doi: 10.1016/S0140-6736(23)02235-3. PMID: 37116523.N Engl J Med. 2017 Aug 3;377(5):454-464. VIALE A DOI: 10.1056/NEJMoa2012971Wang et a. Blood 2022 Oct 27;140(17):1845-1857.	86
ELN 2022 Table2 Table 3	87
Dohner et al. Blood 2022 Sep 22;140(12):1345-1377. Dohner H et al Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations Blood 2024	
How I treat the toxicities of pegasparginase in adults with acute lymphoblastic leukemia Blood, March 2020	88
Badar et al, Blood 2025 https://doi.org/10.1182/blood.2023022921	89
Foa NEJM N Engl J Med 2020;383:1613-23. ALL . Journal of Clinical Oncology, 42(8), 881-885.	90
N Engl J Med 2024;391:320-33	91
ASH EDU 2024 NEUROLOGIC MANIFETATION	92
The consultant's guide to smoldering multiple myeloma Hematology 2022 ASH Education rogram	93
I Br J Haematol. 2023;202:734–744 Monoclonal Gammopathy of Undetermined .Significance N Engl J Med 2025;393:1315-26	94
Nat Rev Clin Oncol- 2025 Sep;22(9):680-700.doi: 10.1038	95
.N Engl J Med- 2021 Jul 1;385(1):46-58	96
The Lancet Oncology, Volume 25, Issue 5, e205 - e216 , 2024 Chari A, et al. Lancet .Haematology 2025	97
JCO- 2025 Aug 20;43(24):2739-2751	98
-Melani C. et al., JCO 2020; 38(29): 3383-3392 Dunleavy K. et al., Blood 2018; 132(8): 800 804	99
The treatment of Burkitt lymphoma in adults, BLOOD2021	100